IN2014CN02806A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02806A
IN2014CN02806A IN2806CHN2014A IN2014CN02806A IN 2014CN02806 A IN2014CN02806 A IN 2014CN02806A IN 2806CHN2014 A IN2806CHN2014 A IN 2806CHN2014A IN 2014CN02806 A IN2014CN02806 A IN 2014CN02806A
Authority
IN
India
Prior art keywords
compounds
medicaments
variables
inhibitors
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Michael J Orwat
Donald J P Pinto
Ii Leon M Smith
Shefali Srivastava
James R Corte
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IN2014CN02806A publication Critical patent/IN2014CN02806A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IN2806CHN2014 2011-10-14 2012-10-12 IN2014CN02806A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547305P 2011-10-14 2011-10-14
PCT/US2012/059859 WO2013055984A1 (en) 2011-10-14 2012-10-12 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Publications (1)

Publication Number Publication Date
IN2014CN02806A true IN2014CN02806A (de) 2015-07-03

Family

ID=47080862

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2806CHN2014 IN2014CN02806A (de) 2011-10-14 2012-10-12

Country Status (7)

Country Link
US (5) US9108951B2 (de)
EP (2) EP2766345B1 (de)
JP (1) JP6033317B2 (de)
CN (1) CN103987697B (de)
ES (2) ES2699226T3 (de)
IN (1) IN2014CN02806A (de)
WO (1) WO2013055984A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3786165A1 (de) 2010-02-11 2021-03-03 Bristol-Myers Squibb Company Synthetische zwischenprodukte zur vorbereitung von makrocyclen als faktor-xia-inhibitoren
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
CA2851810C (en) 2011-10-14 2020-01-07 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
EA025392B1 (ru) 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани Дигидропиридон р1 в качестве ингибиторов фактора xia
EA028581B1 (ru) 2012-08-03 2017-12-29 Бристол-Маерс Сквибб Компани ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (de) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidinsubstituierte tetrahydroisochinoline als factor xia inhibitoren
BR112015007937A2 (pt) 2012-10-12 2017-07-04 Bristol Myers Squibb Co formas cristalinas de um inibidor de fator xia
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US20160229839A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
US20160257668A1 (en) 2013-10-07 2016-09-08 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
RS57659B1 (sr) 2014-01-31 2018-11-30 Bristol Myers Squibb Co Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia
NO2760821T3 (de) 2014-01-31 2018-03-10
US9944643B2 (en) 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3104702B1 (de) 2014-02-11 2022-08-10 Merck Sharp & Dohme LLC Faktor-xia-hemmer
EP3134408B1 (de) * 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. Faktor-xia-hemmer
ES2848348T3 (es) * 2014-05-16 2021-08-06 Cumberland Pharmaceuticals Inc Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca
GEP20196942B (en) 2014-07-01 2019-02-11 Pharmaceutical Company Limited Takeda Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
WO2016015593A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
CN105461688B (zh) * 2014-08-26 2017-12-29 上海医药工业研究院 苯并咪唑化合物k的合成方法
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
AU2015326869B2 (en) * 2014-10-01 2021-04-29 Medimmune Limited Antibodies to ticagrelor and methods of use
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
KR102448406B1 (ko) 2015-06-30 2022-09-27 큠버랜드 파마슈티컬즈 인코포레이티드 Aerd/천식에서 트롬복산 수용체 길항제
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
JP6629958B2 (ja) 2015-07-29 2020-01-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アルキルまたはシクロアルキルP2’基を担持する大員環の第XIa因子阻害剤
WO2017019821A1 (en) 2015-07-29 2017-02-02 Bristol-Myers Squibb Company Factor xia new macrocycle bearing a non-aromatic p2' group
MA43128A (fr) 2015-10-29 2018-09-05 Merck Sharp & Dohme Inhibiteurs du facteur xia
EP3371162B1 (de) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Makrocyclische spirocarbamat-derivate als faktor-xia-inhibitoren, pharmazeutisch verträgliche zusammensetzungen und deren verwendung
CA3005353A1 (en) 2015-11-20 2017-05-26 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP6844890B2 (ja) * 2016-01-07 2021-03-17 藤森工業株式会社 採血管、試薬及びそれらを利用した血液性状分析方法
CN107540659A (zh) * 2016-06-29 2018-01-05 四川科伦博泰生物医药股份有限公司 四氢异喹啉类化合物、其制备方法、药物组合物及其用途
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
WO2019032528A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc BICYCLIC HISTONE DEACETYLASE INHIBITORS
CN109721539B (zh) * 2017-10-27 2021-07-09 天津药物研究院有限公司 吡唑酰胺类衍生物及其制备方法和用途
CN109867660A (zh) * 2017-12-01 2019-06-11 四川科伦博泰生物医药股份有限公司 含季铵离子的四氢异喹啉酰胺化合物及其药物用途
EP3778597A4 (de) 2018-03-28 2021-08-18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Tetrahydroisochinolinderivat, herstellungsverfahren dafür und verwendungen davon
MA53721A (fr) * 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
TW202035409A (zh) * 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
PL3870578T3 (pl) * 2018-10-22 2024-03-04 C4X Discovery Limited Związki terapeutyczne
WO2020094156A1 (zh) * 2018-11-11 2020-05-14 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
EP4185587A1 (de) * 2020-07-22 2023-05-31 JANSSEN Pharmaceutica NV Verbindungen als faktor-xia-hemmer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (fr) 1967-03-29 1968-05-17 Roussel Uclaf Nouvelles pénicillines et procédé de préparation
EP0028489B1 (de) 1979-11-05 1983-10-05 Beecham Group Plc Enzym-Derivate und ihre Herstellung
US4843062A (en) 1987-12-23 1989-06-27 American Home Products Corporation N-acyl-N-napthoylglycines as aldose reductase inhibitors
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036891A1 (en) 1996-04-03 1997-10-09 Merk & Co., Inc. Inhibitors of farnesyl-protein transferase
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
BR9909660A (pt) 1998-03-19 2000-11-21 Vertex Pharma Inibidores de caspases
BR9911590A (pt) 1998-05-26 2001-02-13 Warner Lambert Co Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1016663A1 (de) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Neue Malonsäure Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen sie enthaltend (Inhibierung der Faktor Xa Aktivität)
CA2358578A1 (en) 1999-01-02 2000-07-13 Aventis Pharma Deutschland Gmbh Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
WO2000061608A2 (de) 1999-04-09 2000-10-19 Basf Aktiengesellschaft Niedermolekulare inhibitoren von komplementproteasen
EP1192135A2 (de) 1999-06-14 2002-04-03 Eli Lilly And Company Inhibitoren von serin proteasen
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1125925A1 (de) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amin-Derivate zur Behandlung von Apoptosis
ATE310728T1 (de) * 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
WO2003016248A2 (en) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
PL204263B1 (pl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
CN1832920A (zh) * 2003-08-08 2006-09-13 特兰斯泰克制药公司 芳基和杂芳基化合物,组合物及其使用方法
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
EP1896420B1 (de) 2005-06-17 2017-01-18 Basf Se Verfahren zur herstellung von bleichaktivatoren
JP4955009B2 (ja) 2005-11-11 2012-06-20 エフ.ホフマン−ラ ロシュ アーゲー 凝固因子Xaの阻害剤としての炭素環式縮合環アミン
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
KR20080087817A (ko) 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체
PT2061465E (pt) 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
JP5342450B2 (ja) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
MX2009012847A (es) 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
KR20100027159A (ko) 2007-06-28 2010-03-10 노파르티스 아게 칼리크레인 7 조절제
WO2009114677A1 (en) 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ixa因子抑制劑之雜環化合物
EP3786165A1 (de) 2010-02-11 2021-03-03 Bristol-Myers Squibb Company Synthetische zwischenprodukte zur vorbereitung von makrocyclen als faktor-xia-inhibitoren
WO2013009527A2 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
CA2851810C (en) 2011-10-14 2020-01-07 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CA2859604C (en) 2011-12-21 2019-12-17 Ono Pharmaceutical Co., Ltd. Compounds
EP2807156A1 (de) 2012-01-27 2014-12-03 Novartis AG Aminopyridinderivate als plasma-kallikrein-inhibitoren
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 3位置換プロリン誘導体
CN104684932B (zh) 2012-05-10 2019-03-12 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
AU2013291098A1 (en) 2012-07-19 2015-02-05 Sumitomo Dainippon Pharma Co., Ltd. 1-(cycloalkyl-carbonyl)proline derivative
EA028581B1 (ru) 2012-08-03 2017-12-29 Бристол-Маерс Сквибб Компани ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
EA025392B1 (ru) 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани Дигидропиридон р1 в качестве ингибиторов фактора xia

Also Published As

Publication number Publication date
EP2766345B1 (de) 2016-03-16
ES2699226T3 (es) 2019-02-08
US10000466B2 (en) 2018-06-19
US20170305880A1 (en) 2017-10-26
US20140275061A1 (en) 2014-09-18
US9108951B2 (en) 2015-08-18
EP2899183A1 (de) 2015-07-29
WO2013055984A1 (en) 2013-04-18
EP2766345A1 (de) 2014-08-20
ES2572908T3 (es) 2016-06-03
CN103987697B (zh) 2017-04-26
US10906886B2 (en) 2021-02-02
JP2014528479A (ja) 2014-10-27
JP6033317B2 (ja) 2016-11-30
US20160289209A1 (en) 2016-10-06
US20150315200A1 (en) 2015-11-05
US20180265494A1 (en) 2018-09-20
US9725435B2 (en) 2017-08-08
CN103987697A (zh) 2014-08-13
EP2899183B1 (de) 2018-09-19
US9394276B2 (en) 2016-07-19

Similar Documents

Publication Publication Date Title
IN2014CN02806A (de)
IN2014CN02805A (de)
TN2014000155A1 (en) Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
MX2015000892A (es) Dihidropiridona p1 como inhibidores del factor xia.
MX2015000919A (es) Dihidropiridona p1 como inhibidores del factor xia.
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
UA108442C2 (ru) Индазолы
EP4219465A3 (de) Prmt5-inhibitoren und verwendungen davon
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
IN2015DN01156A (de)
IN2014MN02658A (de)
AU2012214029A8 (en) Rorgammat inhibitors
MY177344A (en) Compounds and their methods of use
IN2015DN00598A (de)
MY162936A (en) Macrocycles as factor xia inhibitors
UA111382C2 (uk) Інгібітори протеїнкінази
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
IN2015DN00185A (de)
IN2014CN03803A (de)
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2014014253A (es) Novedosas n-piridinil-amidas sustituidas en el anillo como inhibidoras de cinasa.
IN2014DN06869A (de)
GB201209587D0 (en) Therapeutic compounds
MX362879B (es) Usos novedosos.